Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

7.72USD
1:33pm EDT
Change (% chg)

$0.02 (+0.26%)
Prev Close
$7.70
Open
$7.69
Day's High
$7.72
Day's Low
$7.57
Volume
1,774
Avg. Vol
110,674
52-wk High
$12.80
52-wk Low
$3.10

Latest Key Developments (Source: Significant Developments)

FDA Accepts Remoxy NDA For Review, Sets PDUFA Date Of Aug 7, 2018
Thursday, 1 Mar 2018 08:00am EST 

March 1 (Reuters) - Pain Therapeutics Inc ::FDA ACCEPTS REMOXY® NDA FOR REVIEW, SETS PDUFA DATE OF AUGUST 7, 2018.U.S. FDA DETERMINED THAT A NDA FOR REMOXY ER IS SUFFICIENTLY COMPLETE TO PERMIT A SUBSTANTIVE REVIEW.FDA HAS SET AN ACTION DATE OF AUGUST 7, 2018 UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA).PAIN THERAPEUTICS -BELIEVES FDA WILL HOLD AN OPEN ADVISORY COMMITTEE MEETING TO DISCUSS REMOXY ER, ALTHOUGH A DATE HAS NOT YET BEEN DETERMINED..  Full Article

Pain Therapeutics Resubmits New Drug Application For Remoxy ER
Tuesday, 13 Feb 2018 08:00am EST 

Feb 13 (Reuters) - Pain Therapeutics Inc ::PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXY® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN.PAIN THERAPEUTICS INC - COMPANY EXPECTS A SIX-MONTH REVIEW CYCLE BY FDA FOR REMOXY NDA.PAIN THERAPEUTICS INC - EXPECTS TO BE NOTIFIED BY FDA OF A PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE WITHIN 60 DAYS.  Full Article

Pain Therapeutics Signs On Demand Sales Agreement With JonesTrading Institutional Services
Friday, 9 Feb 2018 06:20am EST 

Feb 9 (Reuters) - Pain Therapeutics Inc ::PAIN THERAPEUTICS SAYS ON FEB 8, CO ENTERED INTO AN ATM CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING.PAIN THERAPEUTICS - ‍UNDER TERMS OF SALES AGREEMENT, CO MAY ISSUE AND SELL UP TO $16.9 MILLION OF SHARES OF ITS COMMON STOCK - SEC FILING​.  Full Article

Pain therapeutics reports Q3 loss per share $0.40
Wednesday, 1 Nov 2017 08:00am EDT 

Nov 1 (Reuters) - Pain Therapeutics Inc :Pain therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.40.Pain Therapeutics Inc - ‍still expects net cash usage in calendar year 2017 may be approximately $10 million​.Pain Therapeutics - ‍following resubmission of Remoxy NDA in Q1 2018, Co believes net cash usage in 2018 will decrease significantly compared to 2017.  Full Article

Pain Therapeutics announces upcoming meeting with FDA
Monday, 30 Oct 2017 08:00am EDT 

Oct 30 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces upcoming meeting with FDA.Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​.Pain Therapeutics Inc - ‍meeting is planned for November 14, 2017 at FDA headquarters​.Pain Therapeutics Inc - ‍remoxy NDA remains on-track for a planned resubmission in Q1 2018​.  Full Article

Pain Therapeutics reports Q2 loss per share $0.64
Wednesday, 9 Aug 2017 08:00am EDT 

Aug 9 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics reports Q2 2017 financial results and mid-year corporate update.Q2 loss per share $0.64.  Full Article

Pain Therapeutics announces FDA clears investigational new drug application for PTI-125
Monday, 31 Jul 2017 08:00am EDT 

July 31 (Reuters) - Pain Therapeutics Inc :Pain Therapeutics announces FDA has cleared an investigational new drug (IND) application for PTI-125.Pain Therapeutics Inc - ‍company's phase I study with PTI-125 will be funded by a $1.7 million grant from NIH​.Pain Therapeutics Inc - ‍FDA cleared its investigational new drug (IND) application for PTI-125, a novel drug candidate to treat Alzheimer's disease​.Pain Therapeutics- ‍clinical testing with PTI-125 will begin shortly, with funding provided by a $1.7 million research grant from National Institutes of Health​.  Full Article

Pain Therapeutics announces reverse stock split
Monday, 8 May 2017 09:14am EDT 

May 8 (Reuters) - Pain Therapeutics Inc :Pain therapeutics announces reverse stock split.Pain therapeutics inc - that it will effect a 7-for-1 reverse split of its outstanding shares of common stock effective may 9, 2017.  Full Article

Pain Therapeutics reports Q1 loss per share $0.06
Tuesday, 25 Apr 2017 05:47pm EDT 

April 25 (Reuters) - Pain Therapeutics Inc -:Pain Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.06.  Full Article

Pain Therapeutics files for mixed shelf of up to $75 mln
Friday, 14 Apr 2017 06:25pm EDT 

Pain Therapeutics Inc :Files for mixed shelf of up to $75 million - sec filing.  Full Article